Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes
© Bartlett et al; licensee BioMed Central Ltd. 2007
Received: 05 April 2007
Accepted: 02 July 2007
Published: 02 July 2007
Two recombinant, live attenuated human parainfluenza virus type 1 (rHPIV1) mutant viruses have been developed, using a reverse genetics system, for evaluation as potential intranasal vaccine candidates. These rHPIV1 vaccine candidates have two non-temperature sensitive (non-ts) attenuating (att) mutations primarily in the P/C gene, namely CR84GHNT553A (two point mutations used together as a set) and CΔ170 (a short deletion mutation), and two ts att mutations in the L gene, namely LY942A (a point mutation), and LΔ1710–11 (a short deletion), the last of which has not been previously described. The latter three mutations were specifically designed for increased genetic and phenotypic stability. These mutations were evaluated on the HPIV1 backbone, both individually and in combination, for attenuation, immunogenicity, and protective efficacy in African green monkeys (AGMs).
The rHPIV1 mutant bearing the novel LΔ1710–11 mutation was highly ts and attenuated in AGMs and was immunogenic and efficacious against HPIV1 wt challenge. The rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidates were highly ts, with shut-off temperatures of 38°C and 35°C, respectively, and were highly attenuated in AGMs. Immunization with rHPIV1-CR84G/Δ170HNT553ALY942A protected against HPIV1 wt challenge in both the upper and lower respiratory tracts. In contrast, rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 was not protective in AGMs due to over-attenuation, but it is expected to replicate more efficiently and be more immunogenic in the natural human host.
The rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidates are clearly highly attenuated in AGMs and clinical trials are planned to address safety and immunogenicity in humans.
Human parainfluenza virus type 1 (HPIV1) is responsible for approximately 6% of pediatric hospitalizations due to respiratory tract disease with significant illness occurring predominantly in infants and young children . Clinical manifestations range from mild disease, including rhinitis, pharyngitis, and otitis media, to more severe disease, including croup, bronchiolitis, and pneumonia [1–6]. Collectively, human parainfluenza virus serotypes 1, 2 and 3 (HPIV1, 2 and 3) are the second leading causative agents of pediatric hospitalizations due to respiratory disease following respiratory syncytial virus (RSV) [7, 1]. However, a licensed vaccine is currently not available for the prevention of illness caused by any HPIV.
HPIV1 is an enveloped, non-segmented, single-stranded, negative-sense RNA virus belonging to the family Paramyxoviridae, genus Respirovirus, of which HPIV3 is also a member. The HPIV1 genome is 15,600 nucleotides in length and contains six genes in the order 3'-N-P/C-M-F-HN-L-5', which encode three nucleocapsid-associated proteins including the nucleocapsid protein (N), the phosphoprotein (P), and the large polymerase protein (L) and three envelope-associated proteins including the internal matrix protein (M) and the fusion (F) and hemagglutinin-neuraminidase (HN) transmembrane surface glycoproteins . F and HN are the two viral neutralization antigens and are major viral protective antigens. The P/C gene of HPIV1 contains a second open reading frame (ORF) that encodes up to four accessory C proteins, C', C, Y1 and Y2, that initiate at four separate translational start codons in the C ORF and are carboxy co-terminal . However, it is unclear whether the Y2 protein is actually expressed during HPIV1 infection . The HPIV1 C proteins have recently been shown to act as antagonists of the innate immune response during virus infection by inhibiting type 1 interferon (IFN) production and signaling of IFN through its receptor .
Our laboratory is developing a live attenuated virus vaccine for HPIV1 for intranasal administration to infants and young children. The intranasal route of administration is needle-free and has the advantage of direct stimulation of local immunity as well as induction of a substantial systemic immune response . Furthermore, compared to an inactivated vaccine, a live virus vaccine stimulates a broader spectrum of innate and adaptive immune responses . The recent licensure of the trivalent live attenuated influenza virus vaccine (Flumist™) indicates that it is possible to achieve an acceptable balance between attenuation and immunogenicity with a live attenuated respiratory virus vaccine .
Reverse genetics provides a method for introducing attenuating mutations in desired combinations into wild type (wt) HPIV1 [13–16]. Temperature sensitive (ts) attenuating (att) and non-ts att mutations have been developed that, in combination, can enhance both the phenotypic and genetic stability of a HPIV1 vaccine candidate. The licensed cold-adapted influenza A viruses contain similar non-ts and ts att mutations [17, 18]. In the case of HPIV1, non-ts att mutations have been introduced into the P/C gene that inactivate the anti-IFN activities of the C accessory proteins . One of these mutations (CΔ170) is a deletion mutation that affects codon 170 of the HPIV1 C protein; deletion mutations are desirable because they are essentially free of same-site reversion and thus provide for enhanced genetic and phenotypic stability. The CΔ170 mutation inhibited both the production of Type 1 IFN and the signaling of IFN through its receptor and specified an att phenotype in hamsters and African green monkeys (AGMs) [10, 16]. A second non-ts att mutation involves a pair of amino acid substitutions, CR84G and HNT553A, that attenuates HPIV1 for AGMs when they are present together but not individually. This attenuating pair of mutations was not further genetically stabilized, i.e., it is possible to revert to a wt phenotype with a single nucleotide substitution at either mutation. A substitution at amino acid position 942 of L, LY942A, generated a ts att mutation that was engineered for increased genetic and phenotypic stability by the strategy of identifying a codon whose amino acid assignment yielded a ts att phenotype and which would require three nucleotide substitutions for reversion . A virus bearing this stabilized mutation was attenuated in both AGMs and hamsters .
The present study consists of two parts. First, we developed an additional ts att mutation involving a small deletion in the HPIV1 L protein. This mutation was originally identified as a ts att point mutation in the bovine PIV3 (BPIV3) L protein (LS1711I) . The corresponding site in the HPIV1 L protein was identified as position 1710 by sequence alignment, and this codon and its downstream neighbor (codon 1711) were deleted to yield the LΔ1710–11 mutation. This gave us two genetically stabilized ts att mutations in L, the LΔ1710–11 and the LY942A mutations. In the second part of the study, the two non-ts att mutations in C, namely the CR84G/HNT553A set and the CΔ170 mutation, were combined with each other and with either the LΔ1710–11 mutation or the LY942A mutation to develop two live intranasal HPIV1 vaccine candidates. Each of these vaccine candidates contained at least one genetically stabilized ts and non-ts att mutation. These viruses were evaluated for their in vitro attenuation phenotype and for replication, efficacy and immunogenicity in AGMs.
Construction and recovery of mutant rHPIV1 viruses
Summary of the mutations introduced into the rHPIV1 genomea.
nt changes wt → mutantc
Type of mutation
Amino acid change
# nt changes for reversion to wt
A GA → G GA
R → G
GA G → GG G
E → G
AGG GAT TT C → AGC
RDF → S (D deletion; 3 nt deletions in the flanking R-F codons results in a S substitution)
GGA TTT→ deletion
A CC → G CC
T → A
Y → A
GCT GAG→ deletion
In the present study, the LΔ1710–11 deletion mutation in HPIV1 was created at a site that corresponds by sequence alignment to a ts att point mutation originally identified in BPIV3 . Importation of this BPIV3 point mutation has previously been shown to attenuate HPIV2 . Here, the LΔ1710–11 mutation contains a six-nucleotide deletion that results in a deletion of amino acids AE at codon positions 1710–11 of the L gene of HPIV1 (Table 1).
Level of temperature sensitivity of replication of rHPIV1 mutants in vitro.
Mean reduction (log10) in virus titer ± S.E. at the indicated temperature compared to 32°Cc
Virus titer ± S.E. at 32°Cb
7.7 ± 0.1
0.1 ± 0.1
0.1 ± 0.1
0.2 ± 0.1
0.7 ± 0.1
1.3 ± 0.1
3.0 ± 0.3
9.2 ± 0.4
0.4 ± 0.2
0.4 ± 0.6
0.8 ± 0.5
0.3 ± 0.4
1.8 ± 0.6
4.5 ± 0.9
7.8 ± 0.1
-0.3 ± 0.2
-0.3 ± 0.2
-0.2 ± 0.2
0.1 ± 0.2
0.7 ± 0.2
2.5 ± 0.6
7.9 ± 0.3
0.2 ± 0.2
0.7 ± 0.8
0.5 ± 0.2
1.0 ± 0.3
2.6 ± 0.7
4.5 ± 1.0
8.0 ± 0.1
0.2 ± 0.3
1.2 ± 0.3
2.6 ± 1.1 c,d
6.4 ± 0.4
7.4 ± 0.2
0.4 ± 0.4
0.5 ± 0.4
2.3 ± 0.4
4.0 ± 0.6
6.0 ± 0.4
7.5 ± 0.7
0.8 ± 0.7
3.0 ± 0.6
4.8 ± 0.2
6.3 ± 0.1
0.3 ± 0.2
0.9 ± 0.6
2.0 ± 0.3
4.9 ± 0.2
6.4 ± 0.3
2.6 ± 0.6
4.0 ± 0.4
Characterization of rHPIV1s containing single att mutations
Level of replication of HPIV1 vaccine candidates in the upper and lower respiratory tract of African green monkeys.
Mean peak virus titer (log10 TCID50/ml)c
Mean sum of the daily virus titers (log10 TCID50/ml)d
No. of animals
4.2 ± 0.2
3.9 ± 0.3
26.4 ± 1.5
12.2 ± 1.6
3.6 ± 0.4
4.0 ± 0.5
21.0 ± 1.7
11.7 ± 2.5
2.1 ± 0.2 i
4.8 ± 0.3
10.5 ± 0.9
14.3 ± 1.1
3.4 ± 0.5
2.3 ± 0.5
14.8 ± 1.9
5.1 ± 0.8
2.3 ± 0.1
2.3 ± 0.2
16.9 ± 0.7
8.4 ± 1.2
2.4 ± 0.2
2.1 ± 0.3
12.9 ± 1.0
5.1 ± 0.6
1.5 ± 0.4
0.9 ± 0.2
8.6 ± 1.8
3.2 ± 0.6
1.2 ± 0.3
0.6 ± 0.1
5.9 ± 0.5
2.6 ± 0.1
0.9 ± 0.3
≤0.5 ± 0.0
6.3 ± 0.5
≤2.5 ± 0.0
The level of replication of rHPIV1-LY942A and rHPIV1-CR84GLΔ1710–11 in AGMs was next evaluated and compared to that of rHPIV1 wt and the other two single att mutants (Table 3, Groups 1, 3, 4, 5, 7). A rHPIV1 mutant was considered attenuated if it exhibited a significant (P < 0.05) reduction in replication in either the mean peak virus titer or the mean sum of the daily virus titers (a measure of the total amount of virus shed over the duration of the infection) in either the nasopharyngeal (NP) swab (representative of the upper respiratory tract, URT) or tracheal lavage (TL) samples (representative of the lower respiratory tract, LRT) compared to the HPIV1 wt group. We have previously demonstrated that rHPIV1-CR84G replicates to levels equivalent to HPIV1 wt in AGMs, whereas rHPIV1-CR84GHNT553A and rHPIV1-CR84GHNT553ALY942A were attenuated in AGMs [15, 16]. Here, both rHPIV1-LY942A and rHPIV1-CR84GLΔ1710–11 were significantly attenuated in the URT and LRT of AGMs in comparison to HPIV1 wt. The levels of attenuation of rHPIV1-LY942A and rHPIV1-CR84GHNT553ALY942A were comparable, indicating that the LY942A mutation is an attenuating mutation by itself and that the attenuation specified by the LY942A mutation is not additive to that specified by the CR84GHNT553A att mutation. The rHPIV1-CR84GLΔ1710–11 mutant also was significantly attenuated in AGMs, reducing virus titer in comparison to HPIV1 wt by 2.7 and 3.0 log10 50%-tissue-culture-infectious-doses (TCID50)/ml in the URT and LRT, respectively (Table 3). Since rHPIV1-CR84G was confirmed not to be attenuated in AGMs (Table 3, Group 2) , this suggests that the LΔ1710–11 mutation contributes significantly to the observed attenuation phenotype.
Immunogenicity and protective efficacy of rHPIV1 vaccine candidates in AGMs.
Mean peak challenge virus titer (log10TCID50/ml)c
Mean sum of the daily challenge virus titers (log10TCID50/ml)d
Post-challenge serum HAI titerb
Pre-challenge serum HAI titerb
6.7 ± 0.6 (12/12)
0.8 ± 0.2 f
0.7 ± 0.1
2.3 ± 0.2
2.4 ± 0.2
6.6 ± 0.5
3.8 ± 0.9 (3/4)
≤0.5 ± 0.0
≤0.5 ± 0.0
≤2.0 ± 0.0
≤2.0 ± 0.0
4.4 ± 1.2
6.0 ± 0.6 (11/12)
0.6 ± 0.1
0.6 ± 0.1
2.1 ± 0.1
2.1 ± 0.1
7.9 ± 0.4
5.5 ± 0.4 (6/6)
≤0.5 ± 0.0
≤0.5 ± 0.0
≤2.0 ± 0.0
≤2.0 ± 0.0
6.5 ± 0.4
6.3 ± 1.2 (4/4)
1.1 ± 0.2
1.2 ± 0.2
2.7 ± 0.3
2.8 ± 0.3
8.9 ± 1.1
2.0 ± 0.0 (3/8)
0.8 ± 0.2
0.8 ± 0.2
2.6 ± 0.3
2.4 ± 0.3
3.3 ± 0.7
6.1 ± 1.8 (3/4)
3.4 ± 0.6
3.0 ± 0.6
8.4 ± 2.0
8.3 ± 1.3
6.9 ± 1.5
≤1.0 ± 0.0 (0/4)
2.2 ± 0.2
1.8 ± 0.5
5.1 ± 0.3
4.3 ± 1.3
5.5 ± 1.6
≤1.0 ± 0.0 (0/4)
4.5 ± 0.9
3.4 ± 0.4
11.8 ± 2.5
8.1 ± 1.3
7.5 ± 1.4
≤1.0 ± 0.0 (0/4)
5.0 ± 0.6
3.9 ± 0.5
14.8 ± 1.2
11.0 ± 2.5
6.0 ± 1.3
Combination of three single att mutations into rHPIV1 to generate two live attenuated HPIV1 vaccine candidates
Having identified the in vitro and in vivo properties of the four single att mutations, we used this information to generate two live attenuated HPIV1 vaccine candidates containing both non-ts and ts attenuating mutations. These vaccine candidates were designed to incorporate a backbone containing one stabilized non-ts attenuating mutation, CΔ170, as well as the CR84GHNT553A att mutation. The addition of this second mutation (the CR84GHNT553A att mutation) would be expected to increase the overall stability of the virus by increasing the total number of attenuating mutations present in the vaccine candidate. To generate the two live attenuated HPIV1 vaccine candidates, either the stabilized ts att LY942A mutation or the LΔ1710–11 deletion mutation was added to the rHPIV1-CR84G/Δ170HNT553A backbone. We then evaluated the resulting combination mutants, rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11, as potential vaccine candidates.
These two viruses were first evaluated for their level of temperature sensitivity of replication in vitro (Table 2). The level of temperature sensitivity of rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 (Groups 8 and 9 in Table 2) was equivalent to that of the corresponding L gene single-mutation viruses from which they were derived (namely rHPIV1-LY942A and rHPIV1-CR84GLΔ1710–1, Groups 5 and 7 in Table 2). This indicates that combining the non-ts and ts mutations in rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 did not significantly alter their overall level of temperature sensitivity of replication in vitro. A multiple cycle growth curve at 32°C demonstrated that each virus achieved titers in Vero cells that will allow efficient manufacture. Specifically, the rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidates reached peak titers of 7.9 and 7.2 log10 TCID50/ml, respectively, in Vero cells (Figure 1).
The advent of a reverse genetics system for the generation of infectious paramyxoviruses from full-length cDNA plasmids has greatly facilitated the development of live attenuated HPIV1 vaccine candidates [13–16]. The reverse genetics system for HPIV1 has allowed site-directed manipulation of the viral genome via cDNA intermediates, permitting the introduction of attenuating mutations in desired combinations into vaccine candidates. It has also been possible to genetically modify some of the attenuating mutations to optimize genetic and phenotypic stability of viruses bearing the mutations, both by the use of gene deletions and by using codons chosen for a low probability of reversion. This process enables us to optimize the safety profile of the live attenuated HPIV1 vaccine candidates before these viruses are tested in humans.
We are focusing our efforts on the development of live attenuated rHPIV1 vaccines since they have a number of advantages over inactivated or subunit vaccines, including the ability to: (i) induce the full spectrum of protective immune responses including serum and local antibodies as well as CD4+ and CD8+ T cells ; (ii) infect and replicate in the presence of maternal antibody permitting immunization of young infants [22, 23]; (iii) cause an acute, self-limited infection that is readily eliminated from the respiratory tract; and (iv) replicate to high titers in cell substrates acceptable for products for human use, including qualified Vero cells, making manufacture of these vaccines commercially feasible. In the present study, two new rHPIV1 viruses containing single att mutations in L, LΔ1710–11 and LY942A, were generated and characterized, and these ts att mutations were used in combination with previously described non-ts att mutations in the P/C gene and HN gene to generate two new live attenuated HPIV1 vaccine candidates.
A major result of the present study was the creation of the LΔ1710–11 mutation that was found to specify a strong ts att phenotype. The LΔ1710–11 mutation was originally identified as an attenuating point mutation, LT1711I, in BPIV3 . It was evaluated as a deletion mutation in the present study since a deletion mutation offers a higher level of genetic stability than a point mutation, a property that is desirable for mutations in a vaccine candidate. Indeed, since this deletion occurs in an ORF (in which the triplet nature of the codons must be maintained) and in a virus that conforms to the rule of six (in which the hexamer organization must be maintained), same-site reversion would require the precise restoration of six nucleotides. We unfortunately were not able isolate a rHPIV1 mutant with only the LΔ1710–11 mutation since each rHPIV1-LΔ1710–11 mutant that was isolated also possessed one or more adventitious mutations. The LΔ1710–11 mutation could only be recovered free of adventitious mutations when it was in combination with the CR84G mutation, and thus had to be studied in that context. We acknowledge that it is possible that the phenotypes that we observed for the rHPIV1-CR84GLΔ1710–11 are the result of an interaction between the CR84G and LΔ1710–11 mutations. However, we believe that this possibility is unlikely since the CR84G mutation does not contribute to the ts or att phenotype of HPIV1 as an independent mutation. Furthermore, the high level of temperature sensitivity and attenuation of rHPIV1-CR84GLΔ1710–11 versus that of rHPIV1-CR84G suggests a major independent role of the LΔ1710–11 mutation in these two phenotypes. rHPIV1-CR84GLΔ1710–11 manifested a shut-off temperature of 37°C in vitro and was restricted in replication in the URT and LRT of AGMs by 2.5 log10 or 3.0 log10, respectively. Therefore, we suggest that the LΔ1710–11 deletion mutation specifies a ts att phenotype for HPIV1, and, as such, it is a suitable mutation to include in a HPIV1 vaccine candidate.
The LY942A mutation was identified previously as an attenuating mutation for introduction into potential HPIV1 vaccine candidates and was stabilized by codon optimization studies . These studies demonstrated that only three amino acids were shown to specify a wild type phenotype at this codon position (the wild type tyrosine, cysteine and phenylalanine) all of which would require three nucleotide changes to convert the GCG alanine to a codon specifying the wild type phenotype codon in the vaccine virus . In addition, the LY942A mutation was shown to be highly stable under selective pressure during passage at permissive and restrictive temperatures . Previous studies have evaluated the LY942A mutation only in the presence of the CR84GHNT553A set of mutations that attenuates HPIV1 for AGMs [13, 15]. To determine the specific contribution of the LY942A mutation to the ts and att phenotypes associated with the rHPIV1-CR84GHNT553ALY942A virus, a rHPIV1 containing only the LY942A mutation was generated and was found to be as attenuated as rHPIV1-CR84GHNT553ALY942A for AGMs. This indicated that the LY942A mutation independently attenuated HPIV1 for AGMs and can be used in the absence of the CR84GHNT553A mutation to attenuate HPIV1 for AGMs. The attenuation specified by the CR84GHNT553A mutation was not additive with that of LY942A. This actually is a desirable property, since it permits the inclusion of a greater number of mutations while avoiding over-attenuation, and these additional mutations would become unmasked in the case of the loss of one or more other mutations and would thus maintain the att phenotype. Thus, LY942A is a stable mutation that specifies a ts att phenotype for HPIV1 and is suitable for introducing into a HPIV1 vaccine candidate as an independent attenuating mutation.
The LY942A and LΔ1710–11 ts att mutations were used in conjunction with two of the non-ts att mutations, the CR84GHNT553A and CΔ170 mutations , to develop two live attenuated vaccine candidates for HPIV1, namely, rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11. These vaccine candidates thus each contain three independent attenuating mutations (two non-ts att and one ts att mutation), two of which have been genetically stabilized. The combination of mutations present in these two vaccine candidates should enhance the genetic and phenotypic stability of the viruses, although this will require formal demonstration in a clinical trial using clinical grade virus preparations.
Evaluation of the two vaccine candidates revealed that they are reasonable candidates for further study in clinical trials. Both candidates replicated well in Vero cells, a characteristic that is important for manufacturing purposes. Both viruses also demonstrated a strong ts phenotype in vitro (shut-off temperature of ≤38°C) that was similar to that of their ts parent virus, but the two viruses differ in their level of temperature sensitivity in vitro. Since the level of temperature sensitivity of respiratory viruses , including HPIV1 as demonstrated here, correlates with level of attenuation, it was anticipated that this difference in the ts phenotype would be reflected in a difference in the level of attenuation and immunogenicity in vivo, and this indeed was seen. The HPIV1 vaccine candidates were both strongly attenuated in the URT and LRT of AGMs, with rHPIV1-CR84G/Δ170HNT553ALY942A replicating to slightly higher levels than the more ts rHPIV1-CR84G/Δ170HNT553ALΔ1710–11. Both vaccines were weakly immunogenic and failed to induce a detectable level of serum HAI antibodies in AGMs. A low level of protective efficacy was observed in AGMs immunized with rHPIV1-CR84G/Δ170HNT553ALY942A, but the rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 was not protective. This low level of immunogenicity and efficacy was not unexpected since each vaccine was highly restricted in replication and since there is a strong correlation between the level of replication of vaccine virus and its immunogenicity and ability to restrict replication of HPIV1 challenge virus. These results can be interpreted to indicate that the two vaccine candidates are over-attenuated, but we think that this conclusion would be premature. It is likely that these viruses will be more immunogenic, and therefore more efficacious, in humans compared to AGMs since they should replicate more efficiently in humans. The reasons for this are two-fold. First, HPIV1 is a human virus, and it should replicate more efficiently in its natural host in which it causes disease than in AGMs in which it causes only an asymptomatic infection. The actual level of replication of HPIV1 in seronegative humans is unknown, but it replicates efficiently even in adults with pre-existing immunity [25, 26]. Second, these vaccine candidates are highly ts and should replicate more efficiently in humans, which have a lower body core temperature (36.7°C), than in AGMs (approximately 39°C). Therefore, although these vaccine candidates appear to be over-attenuated in AGMs, it is expected that the viruses should replicate somewhat more efficiently in humans and would be more immunogenic than in AGMs. It also is fortunate that the two vaccine candidates appear to differ somewhat in their level of attenuation, since this provides two chances to achieve an optimal balance between safety and efficacy.
The rHPIV1-CR84G/Δ170HNT553ALY942A and rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidates are highly attenuated in AGMs. We plan to initiate studies in humans with the less attenuated vaccine candidate, rHPIV1-CR84G/Δ170HNT553ALY942A. If this virus proves to be insufficiently attenuated in the target population of young seronegative infants (following an initial step-wise progression of safety testing in adults, seropositive children, and seronegative children), we would proceed to evaluate the more attenuated rHPIV1-CR84G/Δ170HNT553ALΔ1710–11 vaccine candidate. If rHPIV1-CR84G/Δ170HNT553ALY942A is over-attenuated, then the LY942A mutation would be deleted and the rHPIV1-CR84G/Δ170HNT553A would be tested in humans. In this way, we will identify a HPIV1 vaccine candidate that exhibits a satisfactory balance between attenuation and immunogenicity for the target population of seronegative infants and young children.
Cells and viruses
LLC-MK2 cells (ATCCCCL7.1) and HEp-2 cells (ATCCCCL23) were maintained in Opti-MEM I (Gibco-Invitrogen, Inc. Grand Island, NY) supplemented with 5% FBS and gentamicin sulfate (50 μg/ml). Vero cells (ATCC CCL-81) were maintained in Opti-PRO SFM (Gibco-Invitrogen, Inc.) in the absence of FBS and supplemented with gentamicin sulfate (50 μg/ml) and L-glutamine (4 mM). BHK-T7 cells, which constitutively express T7 RNA polymerase , were kindly provided by Dr. Ulla Buchholz, NIAID, and were maintained in GMEM (Gibco-Invitrogen, Inc.) supplemented with 10% FBS, geneticin (1 mg/ml), MEM amino acids, and L-glutamine (2 mM). Biologically-derived wt HPIV1 Washington/20993/1964, the parent for the recombinant virus system, was isolated previously from a clinical sample in primary African green monkey kidney (AGMK) cells and passaged 2 additional times in primary AGMK cells  and once in LLC-MK2 cells . This preparation has a wild type phenotype in AGMs, and will be referred to here as HPIV1 wt. It was previously described as HPIV1LLC1 . HPIV1 wt and rHPIV1 mutants were grown in LLC-MK2 cells in the presence of 1.2% Tryple select, a recombinant trypsin (Gibco-Invitrogen, Inc.), as described previously .
Construction of mutant HPIV1 cDNA
P/C, HN and L gene mutations (Table 1) were introduced into the appropriate rHPIV1 subgenomic clones  using the Advantage-HF PCR Kit (Clontech Laboratories, Palo Alto, CA) with a modified PCR mutagenesis protocol described elsewhere . The entire PCR amplified subgenomic clone was sequenced using a Perkin-Elmer ABI 3100 sequencer with the Big Dye sequencing kit (Perkin-Elmer Applied Biosystems, Warrington, UK) to confirm that the subclone contained the introduced mutation and to confirm the absence of adventitious mutations introduced during PCR amplification. Full-length antigenomic cDNA clones (FLCs) of HPIV1 containing the desired mutations were assembled using standard molecular cloning techniques , and the region containing the introduced mutation in each FLC was sequenced as described above to confirm the presence of the introduced mutation and absence of adventitious changes. Each virus was designed to conform to the rule of six, which is a requirement by HPIV1 and numerous other paramyxoviruses that the nucleotide length of their genome be an even multiple of six for efficient replication .
Recovery of rHPIV1 mutant viruses
Three different recovery methods were used to generate rHPIV1 mutants that differed in the source of the T7 polymerase needed to synthesize RNA from the transfected virus-specific plasmids and, in one case, a different transfection method was used. First, using previously described procedures , rHPIV1 virus was recovered from HEp-2 cells that were transfected with plasmids encoding the antigenome and N, P, and L support proteins and infected with an MVA-T7 vaccinia virus recombinant as a source of T7 polymerase. Second, Vero cells were grown to 80% confluency and transfection experiments were performed using the AMAXA Cell Line Nucleofector Kit V, according to manufacturer's directions (AMAXA, Koeln, Germany), as previously described . Briefly, the cells were transfected with 5 μg each of the FLC and the pCL-Neo-BCI-T7 plasmid (expressing T7 polymerase under the control of a eukaryotic promoter) , 0.2 μg each of the N and P, and 0.1 μg of the L support plasmids. The transfection mixture was removed after 24 h at 37°C, and cells were washed and overlaid with Opti-PRO with L-glutamine (4 mM) supplemented with 1.2% Tryple select. The cells and supernatant were transferred to LLC-MK2 cells in T25 cm2 flasks (Corning, NY) 7 days following transfection. Third, BHK-T7 cells constitutively expressing T7 polymerase  were grown to 90 to 95% confluence in six-well plates. The cells were transfected with 5 μg of the FLC, 0.8 μg each of the N and P, and 0.1 μg of the L support plasmids in a volume of 100 μl of Opti-MEM per well. Transfection was carried out with Lipofectamine 2000 (Invitrogen, Inc., Carlsbad, CA), according to the manufacturer's directions. The transfection mixture was removed after a 24 h incubation period at 37°C, and the cells were washed and maintained in GMEM. On day 2 following transfection, the media was supplemented with 1.2% trypsin, and the recovered virus was harvested on days 2–4. All viruses were amplified by passage on LLC-MK2 cells, and each was cloned by two successive rounds of terminal dilution using LLC-MK2 monolayers in 96-well plates (Costar, Corning Inc., Acton, MA). To confirm that the recovered rHPIV1 mutants contained the appropriate mutations and lacked adventitious mutations, viral RNA (vRNA) was isolated from infected cell supernatants using the Qiaquick vRNA kit (Qiagen Inc., Valencia, CA), reverse transcribed using the SuperScript First-Strand Synthesis System (Invitrogen, Inc., Carlsbad, CA) and amplified using the Advantage cDNA PCR Kit (Clontech Laboratories). Each viral genome was sequenced in its entirety.
Evaluation of recombinant HPIV1 vaccine candidates in a multiple cycle growth curve
The recombinant HPIV1 mutants were compared to HPIV1 wt on LLC-MK2 and Vero cells at 32°C in a multiple cycle growth curve. Confluent monolayer cultures in 6-well plates were infected in triplicate at a multiplicity of infection (MOI) of 0.01 50%-tissue-culture-infectious-doses (TCID50) per cell in media containing trypsin. The residual inoculum was withdrawn 2 h post infection as the day 0 sample and was replaced by medium with trypsin. On days 2, and 4–11 post-infection, the total medium supernatant was removed for virus quantitation and was replaced with fresh medium with trypsin. Supernatants containing virus were frozen at -70°C, and all samples were tested together for virus titer with endpoints identified by hemadsorption.
Characterization of the temperature sensitivity of the rHPIV1 vaccine candidates
The ts phenotype for each mutant rHPIV1 virus was determined by comparing its level of replication to that of HPIV1 wt at 32°C and at 1°C increments from 35°C to 40°C, as described previously . Briefly, each virus was serially diluted 10-fold in 96-well LLC-MK2 monolayer cultures in L-15 media (Gibco-Invitrogen, Inc.) containing trypsin with four replicate wells per plate. Replicate plates were incubated at the temperatures indicated above for seven days, and virus infected wells were detected by hemadsorption with guinea pig erythrocytes. The virus titer at each temperature was determined in three to sixteen separate experiments and is expressed as the mean log10 TCID50/ml. The mean titer at an elevated temperature was compared to the mean titer at 32°C, and the reduction in mean titer was determined. The shut-off temperature of an rHPIV1 mutant is defined as the lowest temperature at which the reduction in virus titer compared to its titer at 32°C was 100-fold greater than the reduction in HPIV1 wt titer between the same two temperatures. A mutant is defined as having a ts phenotype if its shut-off temperature is ≤40°C.
Evaluation of replication of viruses in AGMs and efficacy against challenge
AGMs in groups of two to four animals at a time were inoculated intranasally (i.n.) and intratracheally (i.t.) with 106 TCID50 of either HPIV1 wt or mutant rHPIV1 in a 1 ml inoculum at each site. NP swab samples were collected daily from days 1 to 10 post-inoculation, and TL fluid samples were collected on days 2, 4, 6, 8 and 10 post-inoculation. The specimens were flash frozen and stored at -80°C and were subsequently assayed in parallel. Virus present in the samples was titered in dilutions on LLC-MK2 cell monolayers in 96-well plates and an undiluted 100 μl aliquot was also tested in 24-well plates. These were incubated at 32°C for 7 days. Virus was detected by hemadsorption, and the mean log10 TCID50/ml was calculated for each sample day. The limit of detection was 0.5 log10TCID50/ml. The mean peak titer for each group was calculated using the peak titer for each animal, irrespective of the day of sampling. The mean sum of the virus titers for each group was calculated from the sum, calculated for each animal individually, of the virus titers on each day of sampling, up to day 10. The sum of the lower limit of detectability was 5.0 log10 TCID50/ml for NP swabs and 2.5 log10 TCID50/ml for TL samples.
On day 28 post-inoculation, the AGMs were challenged i.n. and i.t. with 106 TCID50 of HPIV1 wt in 1 ml at each site. NP swab and TL samples were collected for virus quantitation on days 2, 4, 6 and 8 post-challenge.
All animal studies were performed under protocol LID22, as approved by the National Institute of Allergy and Infectious Disease (NIAID) Animal Care and Use Committee (ACUC).
Evaluation of immune responses in AGMs
Serum was collected from each monkey on days 0 and 28 post-immunization and on day 28 post-challenge (day 56 post-immunization). HPIV1 HAI antibody titers were determined at 21°C, as described previously , using 0.5% v/v guinea pig erythrocytes and HPIV1 wt as the antigen. The HAI antibody titer was defined as the end-point serum dilution that inhibited hemagglutination and is expressed as the mean reciprocal log2 ± standard error (SE).
The Prism 4 (GraphPad Software Inc., San Diego, CA) one-way ANOVA test, (Student-Newman-Keuls multiple comparison test) was used to assess statistically significant differences between data groups (P < 0.05). The R software programme  was used to perform a Spearman rank test to determine correlation between data sets.
We thank Ernest Williams and Fatemeh Davoodi for performing the HAI assays and Emerito Amaro-Carambot for assistance with sequencing. We are grateful to Pamela Shaw and Dean Follman for assistance with statistical analysis. We also thank Brad Finneyfrock and Marisa St. Claire at Bioqual Inc. for carrying out the primate studies.
This project was funded as a part of the NIAID Intramural Program.
- Chanock RM, Murphy BR, Collins PL: Parainfluenza Viruses. In Fields Virology. Volume 1. 4th edition. Edited by: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Strauss SE. Philadelphia: Lippincott Williams&Wilkins; 2001:1341-1379.Google Scholar
- Henderson FW, Collier AM, Sanyal MA, Watkins JM, Fairclough DL, Clyde WA Jr, Denny FW: A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med 1982,306(23):1377-1383.PubMedView ArticleGoogle Scholar
- Marx A, Torok TJ, Holman RC, Clarke MJ, Anderson LJ: Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997, 176: 1423-1427.PubMedView ArticleGoogle Scholar
- Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF: Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis 1997, 175: 807-813.PubMedView ArticleGoogle Scholar
- Heikkinen T, Thint M, Chonmaitree T: Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999, 340: 260-264. 10.1056/NEJM199901283400402PubMedView ArticleGoogle Scholar
- Counihan ME, Shay DK, Holman RC, Lowther SA, Anderson LJ: Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001, 20: 646-653. 10.1097/00006454-200107000-00003PubMedView ArticleGoogle Scholar
- Murphy BR, Prince GA, Collins PL, Van Wyke Coelingh K, Olmsted RA, Spriggs MK, Parrott RH, Kim HW, Brandt CD, Chanock RM: Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res 1988, 11: 1-15. 10.1016/0168-1702(88)90063-9PubMedView ArticleGoogle Scholar
- Newman JT, Surman SR, Riggs JM, Hansen CT, Collins PL, Murphy BR, Skiadopoulos MH: Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 2002, 24: 77-92. 10.1023/A:1014042221888PubMedView ArticleGoogle Scholar
- Power UF, Ryan KW, Portner A: The P genes of human parainfluenza virus type 1 clinical isolates are polycistronic and microheterogeneous. Virology 1992, 189: 340-343. 10.1016/0042-6822(92)90712-XPubMedView ArticleGoogle Scholar
- Van Cleve W, Amaro-Carambot E, Surman SR, Bekisz J, Collins PL, Zoon KC, Murphy BR, Skiadopoulos MH, Bartlett EJ: Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1. Virology 2006, 352: 61-73. 10.1016/j.virol.2006.04.011PubMedView ArticleGoogle Scholar
- Murphy BR: Mucosal immunity to viruses. In Mucosal Immunology. Second edition. Edited by: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienstock J. Academic Press, Inc; 1999:695-707.Google Scholar
- Mossad SB: Demystifying FluMist, a new intranasal, live influenza vaccine. Cleve Clin J Med 2003, 70: 801-806.PubMedView ArticleGoogle Scholar
- McAuliffe JM, Surman SR, Newman JT, Riggs JM, Collins PL, Murphy BR, Skiadopoulos MH: Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro. J Virol 2004, 78: 2029-2036. 10.1128/JVI.78.4.2029-2036.2004PubMedPubMed CentralView ArticleGoogle Scholar
- Newman JT, Riggs JM, Surman SR, McAuliffe JM, Mulaikal TA, Collins PL, Murphy BR, Skiadopoulos MH: Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses. J Virol 2004, 78: 2017-2028. 10.1128/JVI.78.4.2017-2028.2004PubMedPubMed CentralView ArticleGoogle Scholar
- Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH: Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 2005, 23: 4631-4646. 10.1016/j.vaccine.2005.04.035PubMedView ArticleGoogle Scholar
- Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH: Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 2006, 24: 2674-2684. 10.1016/j.vaccine.2005.10.047PubMedView ArticleGoogle Scholar
- Murphy BR, Park EJ, Gottlieb P, Subbarao K: An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 1997, 15: 1372-1378. 10.1016/S0264-410X(97)00031-5PubMedView ArticleGoogle Scholar
- Murphy BR, Coelingh K: Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol 2002, 15: 295-323. 10.1089/08828240260066242PubMedView ArticleGoogle Scholar
- Skiadopoulos MH, Schmidt AC, Riggs JM, Surman SR, Elkins WR, St Claire M, Collins PL, Murphy BR: Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic. J Virol 2003, 77: 1141-1148. 10.1128/JVI.77.2.1141-1148.2003PubMedPubMed CentralView ArticleGoogle Scholar
- Kolakofsky D, Pelet T, Garcin D, Hausmann S, Curran J, Roux L: Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 1998, 72: 891-899.PubMedPubMed CentralGoogle Scholar
- Nolan SM, Surman SR, Amaro-Carambot E, Collins PL, Murphy BR, Skiadopoulos MH: Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses. Vaccine 2005, 23: 4765-4774. 10.1016/j.vaccine.2005.04.043PubMedView ArticleGoogle Scholar
- Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, et al.: Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182: 1331-1342. 10.1086/315859PubMedView ArticleGoogle Scholar
- Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, et al.: A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003, 22: 394-405. 10.1097/00006454-200305000-00002PubMedGoogle Scholar
- Richman DD, Murphy BR: The association of the temperature-sensitive phenotype with viral attenuation in animals and humans: implications for the development and use of live virus vaccines. Rev Infect Dis 1979, 1: 413-433.PubMedView ArticleGoogle Scholar
- Murphy BR, Richman DD, Chalhub EG, Uhlendorf CP, Baron S, Chanock RM: Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun 1975, 12: 62-68.PubMedPubMed CentralGoogle Scholar
- Smith CB, Purcell RH, Bellanti JA, Chanock RM: Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966, 275: 1145-1152.PubMedView ArticleGoogle Scholar
- Buchholz UJ, Finke S, Conzelmann KK: Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 1999, 73: 251-259.PubMedPubMed CentralGoogle Scholar
- Moeller K, Duffy I, Duprex P, Rima B, Beschorner R, Fauser S, Meyermann R, Niewiesk S, ter Meulen V, Schneider-Schaulies J: Recombinant measles viruses expressing altered hemagglutinin (H) genes: functional separation of mutations determining H antibody escape from neurovirulence. J Virol 2001, 75: 7612-7620. 10.1128/JVI.75.16.7612-7620.2001PubMedPubMed CentralView ArticleGoogle Scholar
- Surman SR, Collins PL, Murphy BR, Skiadopoulos MH: An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials. Journal of virological methods 2007, 141: 30-33. 10.1016/j.jviromet.2006.11.024PubMedView ArticleGoogle Scholar
- Witko SE, Kotash CS, Nowak RM, Johnson JE, Boutilier LA, Melville KJ, Heron SG, Clarke DK, Abramovitz AS, Hendry RM, et al.: An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development. Journal of virological methods 2006, 135: 91-101. 10.1016/j.jviromet.2006.02.006PubMedView ArticleGoogle Scholar
- Skiadopoulos MH, Tao T, Surman SR, Collins PL, Murphy BR: Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts. Vaccine 1999, 18: 503-510. 10.1016/S0264-410X(99)00227-3PubMedView ArticleGoogle Scholar
- Clements ML, Belshe RB, King J, Newman F, Westblom TU, Tierney EL, London WT, Murphy BR: Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991, 29: 1175-1182.PubMedPubMed CentralGoogle Scholar
- The GNU Operating System[http://www.gnu.org/]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.